Compare LOCO & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOCO | CLLS |
|---|---|---|
| Founded | 1980 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.3M | 394.4M |
| IPO Year | 2014 | 2014 |
| Metric | LOCO | CLLS |
|---|---|---|
| Price | $16.78 | $3.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $14.17 | $8.33 |
| AVG Volume (30 Days) | ★ 320.2K | 36.3K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.65 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $401,701,000.00 | N/A |
| Revenue This Year | $3.60 | N/A |
| Revenue Next Year | $3.98 | $0.98 |
| P/E Ratio | $61.78 | ★ N/A |
| Revenue Growth | ★ 5.68 | N/A |
| 52 Week Low | $8.99 | $1.62 |
| 52 Week High | $17.40 | $5.48 |
| Indicator | LOCO | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 64.33 | 55.42 |
| Support Level | $13.52 | $2.86 |
| Resistance Level | N/A | $3.41 |
| Average True Range (ATR) | 0.50 | 0.16 |
| MACD | 0.09 | 0.05 |
| Stochastic Oscillator | 66.36 | 86.96 |
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. It specializes in fire-grilling citrus-marinated chicken and operates in the limited service restaurant market segment. Its offerings include Mexican-inspired menu items, including burritos, tostadas, bowls, salads, and bone-in chicken meals in various portion sizes. It also offers citrus-marinated fire-grilled chicken, along with a range of salsas and dressings that allow customers to customize their meals. The company operates in one operating segment. The majority of the company's revenue is derived from company-operated restaurant revenue.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.